Form 4: Inhibrx Biosciences Director Kimberly Manhard Granted Stock Options Following Sanofi Merger

Director Kimberly Manhard received stock options for 30,000 shares of Inhibrx Biosciences common stock following the merger with a Sanofi subsidiary.

Summary

• Kimberly Manhard, a director of Inhibrx Biosciences, Inc., was granted stock options on May 30, 2024.
• The options allow her to purchase 30,000 shares of common stock at an exercise price of $15.86 per share.
• The grant occurred following the merger of Inhibrx, Inc. with a wholly-owned indirect subsidiary of Sanofi.
• The stock options will be fully exercisable on May 30, 2025, contingent upon Manhard's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate action (stock option grant) following a merger, which is generally viewed neutrally to positively as it incentivizes key personnel. The sentiment is moderately positive due to the alignment of interests between the director and the company's future performance.

Positives

• The granting of stock options to a director aligns their interests with the company's success.
• The vesting period encourages continued service and commitment from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, especially following significant corporate events like mergers and acquisitions. This grant aligns with standard compensation practices in the sector.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotech industry, often benchmarked against companies of similar size and stage of development.
• Comparable companies like Arcus Biosciences or Relay Therapeutics also utilize stock options as part of their compensation packages for directors and executives.
• The vesting schedule and exercise price are likely determined based on industry standards and the company's performance metrics.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to contribute to the company's success.
• The director benefits from the potential future value of the stock options.

Key Dates